vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Loar Holdings Inc. (LOAR). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $131.8M, roughly 1.9× Loar Holdings Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 9.5%, a 1.6% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 19.3%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 19.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ANIP vs LOAR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $131.8M |
| Net Profit | $27.5M | $12.5M |
| Gross Margin | — | 52.1% |
| Operating Margin | 14.1% | 18.0% |
| Net Margin | 11.1% | 9.5% |
| Revenue YoY | 29.6% | 19.3% |
| Net Profit YoY | 367.5% | 239.5% |
| EPS (diluted) | $1.14 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $131.8M | ||
| Q3 25 | $227.8M | $126.8M | ||
| Q2 25 | $211.4M | $123.1M | ||
| Q1 25 | $197.1M | $114.7M | ||
| Q4 24 | $190.6M | $110.4M | ||
| Q3 24 | $148.3M | $103.5M | ||
| Q2 24 | $138.0M | $97.0M | ||
| Q1 24 | $137.4M | $91.8M |
| Q4 25 | $27.5M | $12.5M | ||
| Q3 25 | $26.6M | $27.6M | ||
| Q2 25 | $8.5M | $16.7M | ||
| Q1 25 | $15.7M | $15.3M | ||
| Q4 24 | $-10.3M | $3.7M | ||
| Q3 24 | $-24.2M | $8.7M | ||
| Q2 24 | $-2.3M | $7.6M | ||
| Q1 24 | $18.2M | $2.2M |
| Q4 25 | — | 52.1% | ||
| Q3 25 | — | 52.7% | ||
| Q2 25 | — | 53.8% | ||
| Q1 25 | — | 52.1% | ||
| Q4 24 | — | 48.9% | ||
| Q3 24 | — | 51.1% | ||
| Q2 24 | — | 49.0% | ||
| Q1 24 | — | 48.4% |
| Q4 25 | 14.1% | 18.0% | ||
| Q3 25 | 15.9% | 22.9% | ||
| Q2 25 | 6.6% | 22.2% | ||
| Q1 25 | 13.3% | 22.8% | ||
| Q4 24 | -2.3% | 19.2% | ||
| Q3 24 | -13.8% | 22.1% | ||
| Q2 24 | 3.7% | 22.9% | ||
| Q1 24 | 14.8% | 23.3% |
| Q4 25 | 11.1% | 9.5% | ||
| Q3 25 | 11.7% | 21.8% | ||
| Q2 25 | 4.0% | 13.6% | ||
| Q1 25 | 8.0% | 13.4% | ||
| Q4 24 | -5.4% | 3.3% | ||
| Q3 24 | -16.3% | 8.4% | ||
| Q2 24 | -1.7% | 7.9% | ||
| Q1 24 | 13.2% | 2.4% |
| Q4 25 | $1.14 | $0.13 | ||
| Q3 25 | $1.13 | $0.29 | ||
| Q2 25 | $0.36 | $0.17 | ||
| Q1 25 | $0.69 | $0.16 | ||
| Q4 24 | $-0.45 | $-11023.48 | ||
| Q3 24 | $-1.27 | $0.09 | ||
| Q2 24 | $-0.14 | $0.09 | ||
| Q1 24 | $0.82 | $11023.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $84.8M |
| Total DebtLower is stronger | — | $715.7M |
| Stockholders' EquityBook value | $540.7M | $1.2B |
| Total Assets | $1.4B | $2.0B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $84.8M | ||
| Q3 25 | $262.6M | $99.0M | ||
| Q2 25 | $217.8M | $103.3M | ||
| Q1 25 | $149.8M | $80.5M | ||
| Q4 24 | $144.9M | $54.1M | ||
| Q3 24 | $145.0M | $55.2M | ||
| Q2 24 | $240.1M | $73.2M | ||
| Q1 24 | $228.6M | $28.2M |
| Q4 25 | — | $715.7M | ||
| Q3 25 | — | $279.4M | ||
| Q2 25 | — | $277.7M | ||
| Q1 25 | — | $277.5M | ||
| Q4 24 | — | $277.3M | ||
| Q3 24 | — | $602.1M | ||
| Q2 24 | — | $250.7M | ||
| Q1 24 | — | $534.2M |
| Q4 25 | $540.7M | $1.2B | ||
| Q3 25 | $505.8M | $1.2B | ||
| Q2 25 | $436.8M | $1.1B | ||
| Q1 25 | $418.6M | $1.1B | ||
| Q4 24 | $403.7M | $1.1B | ||
| Q3 24 | $405.9M | $769.8M | ||
| Q2 24 | $455.8M | $758.4M | ||
| Q1 24 | $452.0M | $420.6M |
| Q4 25 | $1.4B | $2.0B | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.1B |
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | 0.78× | ||
| Q2 24 | — | 0.33× | ||
| Q1 24 | — | 1.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $30.4M |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | 2.43× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $30.4M | ||
| Q3 25 | $44.1M | $29.7M | ||
| Q2 25 | $75.8M | $23.8M | ||
| Q1 25 | $35.0M | $28.4M | ||
| Q4 24 | $15.9M | $20.7M | ||
| Q3 24 | $12.5M | $16.3M | ||
| Q2 24 | $17.4M | $7.1M | ||
| Q1 24 | $18.3M | $10.8M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 1.10× | 2.43× | ||
| Q3 25 | 1.66× | 1.08× | ||
| Q2 25 | 8.87× | 1.42× | ||
| Q1 25 | 2.23× | 1.85× | ||
| Q4 24 | — | 5.62× | ||
| Q3 24 | — | 1.89× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | 1.00× | 4.81× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
